Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Xilio Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/18/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 700,000 options to buy
@ $2.785, valued at
$1.9M
|
|
| 08/18/2023 |
4
| Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $2.785, valued at
$835.5k
|
|
| 08/18/2023 |
4
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $2.785, valued at
$69.6k
|
|
| 08/18/2023 |
4
| Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 136,500 options to buy
@ $2.785, valued at
$380.2k
|
|
| 08/07/2023 |
4
| Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 150,000 options to buy
@ $2.75, valued at
$412.5k
|
|
| 04/03/2023 |
4
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 55,000 options to buy
@ $3.17, valued at
$174.4k
|
|
| 01/04/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 350,000 options to buy
@ $2.69, valued at
$941.5k
|
|
| 01/04/2023 |
4
| Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 136,500 options to buy
@ $2.69, valued at
$367.2k
|
|
| 01/04/2023 |
4
| English Edward C (PRINCIPAL ACCOUNTING OFFICER) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 24,000 options to buy
@ $2.69, valued at
$64.6k
|
|
| 09/16/2022 |
4
| Heyman Tomas J. (Director) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 26,400 options to buy
@ $3.15, valued at
$83.2k
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2022 |
4
| Giovine Salvatore (CFO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 49,500 options to buy
@ $12.66, valued at
$626.7k
|
|
| 02/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/06/2022 |
4
| Xu Yuan (Director) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 26,400 options to buy
@ $15.92, valued at
$420.3k
|
|
| 12/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/28/2021 |
4
| Flynn James E (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 756,472 shares
@ $0
Bought 387,500 shares
@ $16, valued at
$6.2M
Converted 7,186,489 preferred shares
@ $0 |
|
| 10/28/2021 |
4
| FIL Ltd (See Remark 1) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 218,705 shares
@ $0
Converted 2,077,698 preferred shares
@ $0 |
|
| 10/28/2021 |
4
| FMR LLC (See Remark 1) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 789,473 shares
@ $0
Converted 686,499 shares
@ $0
Converted 28,703 shares
@ $0
Converted 372,215 shares
@ $0
Converted 4,465 shares
@ $0
Converted 7,500,000 preferred shares
@ $0
Converted 6,521,739 preferred shares
@ $0
Converted 272,687 preferred shares
@ $0
Converted 3,536,046 preferred shares
@ $0
Converted 42,421 preferred shares
@ $0 |
|
| 10/28/2021 |
4
| SV7 Impact Medicine Fund LP (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 998,544 shares
@ $0
Converted 998,544 shares
@ $0
Converted 302,588 shares
@ $0
Converted 302,588 shares
@ $0
Converted 9,486,166 convertible preferred
@ $0
Converted 9,486,166 convertible preferred
@ $0
Converted 2,874,595 convertible preferred
@ $0
Converted 2,874,595 convertible preferred
@ $0 |
|
| 10/26/2021 |
4
| TAKEDA PHARMACEUTICAL CO LTD (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 1,475,121 shares
@ $0
Converted 1,248,180 preferred shares
@ $0
Converted 226,941 preferred shares
@ $0 |
|
| 10/26/2021 |
4
| RiverVest Venture Fund IV, L.P. (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 832,120 shares
@ $0
Converted 359,324 shares
@ $0
Bought 250,000 shares
@ $16, valued at
$4M
Converted 832,120 preferred shares
@ $0
Converted 359,324 preferred shares
@ $0 |
|
| 10/26/2021 |
4
| Merck KGaA (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 416,060 shares
@ $0
Converted 264,765 shares
@ $0
Converted 3,952,568 preferred shares
@ $0
Converted 2,515,271 options to buy
@ $0 |
|
| 10/26/2021 |
4
| Rock Springs Capital Management LP (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 756,472 shares
@ $0
Converted 151,294 shares
@ $0
Bought 500,000 shares
@ $16, valued at
$8M
Converted 7,186,490 preferred shares
@ $0
Converted 1,437,297 preferred shares
@ $0 |
|
| 10/26/2021 |
4
| BAY CITY CAPITAL LLC (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 665,696 shares
@ $0
Converted 151,294 shares
@ $0
Bought 312,500 shares
@ $16, valued at
$5M
Converted 6,324,110 preferred shares
@ $0
Converted 1,437,297 preferred shares
@ $0 |
|
| 10/26/2021 |
4
| Atlas Venture Fund XI, L.P. (10% Owner) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Converted 1,372,998 shares
@ $0
Converted 624,089 shares
@ $0
Converted 548,442 shares
@ $0
Bought 187,500 shares
@ $16, valued at
$3M
Converted 13,043,477 options to buy
@ $0
Converted 5,928,852 preferred shares
@ $0
Converted 5,210,204 preferred shares
@ $0 |
|
| 10/26/2021 |
4
| Clancy Paul J (Director) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 44,033 options to buy
@ $5.51, valued at
$242.6k
Granted 65,528 options to buy
@ $5.89, valued at
$386k
|
|
|
|
|